Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lwabi

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The Lancet. Global Health|August 22, 2021
Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based studyEmmy Okello, Emma Ndagire, Babu Muhamed, et al.
Clinical Proteomics|March 23, 2022
Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD casesM Taariq Salie, Jing Yang, Carlos R Ramírez Medina, et al.
JAMA|June 5, 2024
Mortality and Morbidity in Adults With Rheumatic Heart DiseaseGanesan Karthikeyan, Mpiko Ntsekhe, Shofiqul Islam, et al.
Circulation. Genomic and Precision Medicine|December 22, 2022
Rationale, Design, and the Baseline Characteristics of the RHDGen (The Genetics of Rheumatic Heart Disease) Network Study†Tafadzwa Machipisa, Chishala Chishala, Gasnat Shaboodien, et al.
JAMA Cardiology|June 9, 2021
Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals: Findings From the RHDGen StudyTafadzwa Machipisa, Michael Chong, Babu Muhamed, et al.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
The New England Journal of Medicine|August 29, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationStuart J Connolly, Ganesan Karthikeyan, Mpiko Ntsekhe, et al.
Cardiovascular Journal of Africa|January 28, 2016
Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiquéDavid Watkins, Liesl Zuhlke, Mark Engel, et al.
European Heart Journal|November 27, 2014
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)Liesl Zühlke, Mark E Engel, Ganesan Karthikeyan, et al.
Circulation|October 6, 2016
Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study)Liesl Zühlke, Ganesan Karthikeyan, Mark E Engel, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The Lancet. Global Health|August 22, 2021
Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based studyEmmy Okello, Emma Ndagire, Babu Muhamed, et al.
Clinical Proteomics|March 23, 2022
Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD casesM Taariq Salie, Jing Yang, Carlos R Ramírez Medina, et al.
JAMA|June 5, 2024
Mortality and Morbidity in Adults With Rheumatic Heart DiseaseGanesan Karthikeyan, Mpiko Ntsekhe, Shofiqul Islam, et al.
Circulation. Genomic and Precision Medicine|December 22, 2022
Rationale, Design, and the Baseline Characteristics of the RHDGen (The Genetics of Rheumatic Heart Disease) Network Study†Tafadzwa Machipisa, Chishala Chishala, Gasnat Shaboodien, et al.
JAMA Cardiology|June 9, 2021
Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals: Findings From the RHDGen StudyTafadzwa Machipisa, Michael Chong, Babu Muhamed, et al.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
The New England Journal of Medicine|August 29, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationStuart J Connolly, Ganesan Karthikeyan, Mpiko Ntsekhe, et al.
Cardiovascular Journal of Africa|January 28, 2016
Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiquéDavid Watkins, Liesl Zuhlke, Mark Engel, et al.
European Heart Journal|November 27, 2014
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)Liesl Zühlke, Mark E Engel, Ganesan Karthikeyan, et al.
Circulation|October 6, 2016
Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study)Liesl Zühlke, Ganesan Karthikeyan, Mark E Engel, et al.
Pageof 8